Apolipoproteins e and AV mediate lipoprotein clearance by hepatic proteoglycans

Journal of Clinical Investigation

Volumn 123, Issue 6, 2013, Pages 2742-2751

  Gonzales, Jon C ^a   Gordts, Philip L S M ^a   Foley, Erin M ^a   Esko, Jeffrey D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN E; HEPARAN SULFATE; PROTEOHEPARAN SULFATE; SYNDECAN 1; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIET RESTRICTION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CLEARANCE; MOUSE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE, TUMOR; FEMALE; HUMANS; LIPOPROTEINS; LIVER; MALE; MICE; MICE, TRANSGENIC; PROTEIN BINDING; SYNDECAN-1; TRIGLYCERIDES;

EID: 84878524779     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67398     Document Type: Article

References (69)

1. Kolovou GD, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9(3):258-270.
2. Nordestgaard BG, Freiberg JJ. Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. Curr Vasc Pharmacol. 2011; 9(3):281-286.
3. Havel RJ, Kane JP. Structure and metabolism of plasma lipoproteins. In: Scriver CR, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, New York, USA: McGraw-Hill; 2001:2705-2716.
4. Beigneux AP, et al. Glycosylphosphatidylinositolanchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5(4):279-291.
5. Davies BS, et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 2010;12(1):42-52.
6. Williams KJ, Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr Opin Lipidol. 2010;21(3):218-228.
7. Foley EM, Esko JD. Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins. Prog Mol Biol Transl Sci. 2010;93:213-233.
8. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232(4746):34-47.
9. Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci U S A. 1994;91(10):4431-4435.
10. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92(2):883-893.
11. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cremediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998; 101(3):689-695.
12. MacArthur JM, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007;117(1):153-164.
13. Stanford KI, et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009;119(11):3236-3245.
14. Stanford KI, et al. Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem. 2010;285(1):286-294.
15. Hodoglugil U, Williamson DW, Yu Y, Farrer LA, Mahley RW. Glucuronic acid epimerase is associated with plasma triglyceride and high-density lipoprotein cholesterol levels in Turks. Ann Hum Genet. 2011;75(3):398-417.
16. Chen K, et al. Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. Hepatology. 2010;52(6):1957-1967.
17. Hassing HC, et al. Inhibition of hepatic sulfatase-2 in vivo: A novel strategy to correct diabetic dyslipidemia. Hepatology. 2012;55(6):1746-1753.
18. Weisgraber KH, Rall SC. Human apolipoprotein B-100 heparin-binding sites. J Biol Chem. 1987; 262(23):11097-11103.
19. Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP, Boren J. Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem. 2002;277(35):32228-32233.
20. Weisgraber KH, Rall SC Jr, Mahley RW, Milne RW, Marcel YL, Sparrow JT. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem. 1986;261(5):2068-2076.
21. Fielding PE, Ishikawa Y, Fielding CJ. Apolipoprotein E mediates binding of normal very low density lipoprotein to heparin but is not required for high affinity receptor binding. J Biol Chem. 1989;264(21):12462-12466.
22. Saito H, et al. Characterization of the heparin binding sites in human apolipoprotein E. J Biol Chem. 2003;278(17):14782-14787.
23. Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem. 2005;280(27):25383-25387.
24. Hill JS, Yang D, Nikazy J, Curtiss LK, Sparrow JT, Wong H. Subdomain chimeras of hepatic lipase and lipoprotein lipase. Localization of heparin and cofactor binding. J Biol Chem. 1998;273(47):30979-30984.
25. Sendak RA, Berryman DE, Gellman G, Melford K, Bensadoun A. Binding of hepatic lipase to heparin: identification of specific heparin-binding residues in two distinct positive charge clusters. J Lipid Res. 2000;41(2):260-268.
26. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest. 1992;90(5):2013-2021.
27. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem. 1992;267(19):13284-13292.
28. Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem. 1993;268(14):10160-10167.
29. Ji ZS, Dichek HL, Miranda RD, Mahley RW. Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem. 1997;272(50):31285-31292.
30. Fuki IV, et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest. 1997; 100(6):1611-1622.
31. Skottova N, Savonen R, Lookene A, Hultin M, Olivecrona G. Lipoprotein lipase enhances removal of chylomicrons and chylomicron remnants by the perfused rat liver. J Lipid Res. 1995;36(6):1334-1344.
32. Merkel M, et al. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc Natl Acad Sci U S A. 1998; 95(23):13841-13846.
33. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007; 117(1):94-98.
34. Deng Y, Foley EM, Gonzales JC, Gordts PL, Li Y, Esko JD. Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology. 2012;55(1):277-286.
35. Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest. 1973;52(1):32-38.
36. Young SG, Koduri RK, Austin RK, Bonnet DJ, Smith RS, Curtiss LK. Definition of a nonlinear conformational epitope for the apolipoprotein B-100-specific monoclonal antibody, MB47. J Lipid Res. 1994;35(3):399-407.
37. Young SG, Smith RS, Hogle DM, Curtiss LK, Witztum JL. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin Chem. 1986;32(8):1484-1490.
38. Milne R, et al. The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem. 1989; 264(33):19754-19760.
39. Curtiss LK, Edgington TS. Immunochemical heterogeneity of human plasma apolipoprotein B. I. Apolipoprotein B binding of mouse hybridoma antibodies. J Biol Chem. 1982;257(24):15213-15221.
40. Heeren J, Niemeier A, Merkel M, Beisiegel U. Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo. J Mol Med. 2002; 80(9):576-584.
41. Grosskopf I, et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol. 2005;25(12):2573-2579.
42. Wasteson A. A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate. J Chromatogr. 1971; 59(1):87-97.
43. Plump AS, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2):343-353.
44. Wilsie LC, Gonzales AM, Orlando RA. Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, non-clathrin-mediated pathway. Lipids Health Dis. 2006;5:23.
45. Hamilton RL, Wong JS, Guo LS, Krisans S, Havel RJ. Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res. 1990;31(9):1589-1603.
46. Ji ZS, Fazio S, Lee YL, Mahley RW. Secretioncapture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem. 1994; 269(4):2764-2772.
47. Horie Y, Fazio S, Westerlund JR, Weisgraber KH, Rall SC. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J Biol Chem. 1992;267(3):1962-1968.
48. Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem. 1994;269(18):13421-13428.
49. Mahley RW, Huang Y, Rall SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res. 1999;40:1933-1949.
50. Pennacchio LA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294(5540):169-173.
51. Merkel M, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem. 2005;280(22):21553-21560.
52. Shu X, et al. Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoproteinbinding protein 1. Arterioscler Thromb Vasc Biol. 2010; 30(12):2504-2509.
53. Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis. 2011;219(1):15-21.
54. Talmud PJ, Cooper JA, Hattori H, Miller IP, Miller GJ, Humphries SE. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia. 2006;49(10):2337-2340.
55. O'Brien PJ, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem. 2005;51(2):351-359.
56. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40(1):1-16.
57. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis. 1998;139(2):205-222.
58. Diard P, Malewiak MI, Lagrange D, Griglio S. Hepatic lipase may act as a ligand in the uptake of artificial chylomicron remnant-like particles by isolated rat hepatocytes. Biochem J. 1994;299(pt 3):889-894.
59. Dichek HL, et al. Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake. J Biol Chem. 1998;273(4):1896-1903.
60. Dichek HL, et al. Hepatic lipase overexpression lowers remnant and LDL levels by a noncatalytic mechanism in LDL receptor-deficient mice. J Lipid Res. 2001;42(2):201-210.
61. Dichek HL, Qian K, Agrawal N. The bridging function of hepatic lipase clears plasma cholesterol in LDL receptor-deficient "apoB-48-only" and "apoB-100-only" mice. J Lipid Res. 2004;45(3):551-560.
62. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A. 1991;88(19):8342-8346.
63. Lyon M, Deakin JA, Gallagher JT. Liver heparan sulfate structure. A novel molecular design. J Biol Chem. 1994;269(15):11208-11215.
64. Conrad HE. Heparin-Binding Proteins. San Diego, California, USA: Academic Press; 1998.
65. Mansouri RM, et al. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ Res. 2008;103(5):450-453.
66. Grosskopf I, Shaish A, Afek A, Shemesh S, Harats D, Kamari Y. Apolipoprotein A-V modulates multiple atherogenic mechanisms in a mouse model of disturbed clearance of triglyceride-rich lipoproteins. Atherosclerosis. 2012;224(1):75-83.
67. Wei W, Ninonuevo MR, Sharma A, Danan-Leon LM, Leary JA. A comprehensive compositional analysis of heparin/heparan sulfate-derived disaccharides from human serum. Anal Chem. 2011; 83(10):3703-3708.
68. Farese RV, et al. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc Natl Acad Sci U S A. 1996; 93(13):6393-6398.
69. Rohlmann A, Gotthardt M, Willnow TE, Hammer RE, Herz J. Sustained somatic gene inactivation by viral transfer of Cre recombinase. Biotechnology. 1996;14(11):1562-1565.